Niu · Science (New York, N.Y.) 2017 · Preclinical in vitro and animal genetic engineering study · n=?

Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9.

Cited 766 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical bench and animal genetic engineering study

PubMed 28798043 · doi:10.1126/science.aan4187 · record verified 2026-08-30

What was done

Researchers evaluated the infectivity and horizontal transmission of porcine endogenous retroviruses (PERVs) in human cells. Using CRISPR-Cas9 genome editing, they inactivated all PERVs in a primary porcine cell line and generated PERV-inactivated pigs using somatic cell nuclear transfer.

What was found

The authors confirmed that PERVs can infect human cells and horizontally transfer between them. They achieved complete inactivation of PERVs in primary pig cells and successfully produced live PERV-inactivated pigs. No specific quantitative data (such as PERV copy numbers, editing efficiency percentages, or animal counts) were reported in the abstract.

Why it matters

Transmission of porcine endogenous retroviruses to humans represents a primary biosafety concern for pig-to-human xenotransplantation. This study demonstrates the technical feasibility of generating viable pigs completely devoid of active PERVs to improve xenotransplantation safety.

Limits

The abstract provides no sample size, survival rates, or quantitative metrics. As a preclinical animal and cell culture study, it does not demonstrate in vivo human safety, long-term organ functionality, or immunological compatibility.

Cited by